Anemia

  Healio spoke with Akriti Jain, MD, about aproaching the treatment of myelodysplastic syndrome based on where patients lie on the MDS spectrum.

Healio has compiled a list of its most-read anemia care news in 2023.

SAN DIEGO — Navitoclax added to ruxolitinib led to a significant improvement in spleen volume reduction compared with placebo among patients with untreated myelofibrosis, study results presented at ASH Annual Meeting and Exposition showed.

Healio spoke with Ryan. W. Jacobs, MD, about challenges in the treatment of CLL.

Diagnostic test completion for early age-onset colorectal cancer is low among U.S. veterans presenting with iron-deficiency anemia or hematochezia, with women and Black and Hispanic veterans less likely to undergo follow-up testing.

Healio | Nephrology News & Issues interviewed Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis, about the role of anemia management in kidney care. Wish is also chair of the Editorial Advisory Board for Healio | Nephrology News & Issues.

During the last 3 decades, only one class of drugs – erythropoiesis-stimulating agents – has been available to treat anemia in patients with end-stage kidney disease. That has now changed.

Testosterone therapy increases hemoglobin levels for older men with anemia and is linked to a lower likelihood for developing anemia for men without the condition, according to study data.

PHILADELPHIA — In patients with acute MI and anemia, there was no difference between liberal and restrictive transfusion strategies for the composite outcome of death and MI at 30 days, according to results of the MINT trial.

PHILADELPHIA — Results of a survey conducted in the U.S. and abroad showed that most nephrologists remain wary about prescribing hypoxia-inducible factor-prolyl hydroxylase inhibitors, according to a poster presentation at ASN Kidney Week.